hacktheripper@hushmail.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MIGRE Filled 50K
MIGRE had buy at ask for 50K not filled for 12 minutes
XMSR NEWS
UPDATE 1-XM Satellite has more than 929,000 subscribers
(Updates with background, stock activity)
NEW YORK, Oct 1 (Reuters) - Broadcaster XM Satellite Radio
Holdings Inc. on Wednesday said it added 237,000 subscribers in
the third quarter and remains on track to meet its goal of
serving 1.2 million customers by year-end.
The Washington-based company, whose shares were up more
than 5 percent, said it now has 929,648 subscribers. In the
second quarter it added 209,000.
XM <XMSR.O> is the leader in a nascent market that also
includes Sirius Satellite Radio Inc. <SIRI.O>. Analysts have
said the companies need more than 2 million subscribers to
break even. XM on Wednesday said it expects to reach cash flow
break-even by the end of 2004. Sirius, which unveiled its
service months after XM, has only 105,000 customers.
Satellite radio provides nationwide music, talk and news
channels, including some that are commercial free, to customers
who must buy a receiver and pay a monthly fee for the service.
Many automobile makers are offering XM and Sirius radios in new
cars.
Shares of XM were up 84 cents to $16.34 in active
late-morning trade on the Nasdaq stock market.
((Reporting by Franklin Paul; editing by John Wallace; Reuters
Messaging: franklin.paul.reuters.com@reuters.net; +1 646 223
6180))
(C) Reuters 2003. All rights reserved. Republication or redistribution of
Reuters content, including by caching, framing or similar means, is expressly
prohibited without the prior written consent of Reuters. Reuters and the Reuters
sphere logo are registered trademarks and trademarks of the Reuters group of
companies around the world.
nN01203628
Oct-01-2003 15:34 GMT
Symbols:
DE;XM1 DE;XM1F DE;XM1X US;SIRI US;XMSR
Source RTRS Reuters News
Categories:
D DNP E HOT LEN NAT PCO PCU PTD PUB RNP RTRS T U US USC MST/F/COB
MST/F/MKT MST/I/BRD MST/I/CBL MST/I/HOT MST/I/MKT MST/I/PUB MST/L/EN MST/R/US
REV5 RSF TGT/RSF
FGWC is this a shake or bail?
FGWC could not get filled.. have a good ride longs....
FGWC cann not get filled .06
CYGX .70 x .79
got out a .14 AFTER Drillbit said it was gonna be interviewed and the only place I could find was on a daytrading site....
called Internetplays.com
Magnum d'Or Resources Inc. To Conduct Interactive Interview Regarding Corporate Developments
/FROM CANADA NEWSWIRE TORONTO 416-863-9350/
TO BUSINESS EDITOR:
Magnum d'Or Resources Inc. To Conduct Interactive Interview
Regarding Corporate Developments
TRADING SYMBOL (OTCBB: MAGR)
TORONTO, Sept. 30 /PRNewswire-FirstCall/ - Magnum d'Or Resources, Inc.
(Magnum), a junior resource exploration development company is pleased to
announce that it has been asked to participate in an interactive interview
with InternetPlays.com. Mr. Reno Calabrigo, President of Magnum looks forward
to discussing the recent corporate developments with InternetPlays.com
members, as well as take questions from the general public. Tom Bibiyan of
InternetPlays.com stated, "With the recent interest in Magnum d'Or Resources
Inc. and the entire gold sector by our members, this interview will help
answer many of the questions they may have". InternetPlays.com is one of the
largest interactive day trading destinations in the country, with over 400
daily participants in its chat forum. Please join us for this event to be held
on Wednesday, October 1st, 2003 at 4PM EST.
A number of statements contained in this press release are forward-
looking statements that are made pursuant to the Safe Harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements involved a number of risks and uncertainties including but not
limited to competitive market conditions, successful integration of
acquisitions, and the ability to secure additional sources of financing. The
actual results that Magnum may achieve could differ materially from any
forward-looking statements due to such risks and uncertainties.
MAGNUM d'OR RESOURCES INC.
www.magnumexploration.com
SOURCE Magnum d'Or Resources Inc.
/CONTACT: Reno J. Calabrigo, President, Telephone: (416) 200-1958, Email:
info@magnexploration.com/
Sep-30-2003 17:08 GMT
Symbols:
US;MAGR
Source PRN PR Newswire
Categories:
NWI/MNG NWR/ON MST/I/MNG MST/R/CA TGT/PRN
Sold magr looking for shake to get back in
MAGR interview where? tv, radio???
CYGX why didnt we get a PR from the presentation on Sept 22???
MAGR the walls are coming down
Looks like MAGR to be a mover today
AMEP nite moved from .09 to .098 on bid side...
and holds .10 on ask..
FWIW
APII News
One Giant Leap for Action Products
/FROM PR NEWSWIRE NEW YORK 800-776-8090/
TO BUSINESS AND RETAILING EDITORS:
One Giant Leap for Action Products
Space Voyagers Educational Astronaut Figures Win Dr. Toy Awards
ORLANDO, Fla., Oct. 1 /PRNewswire-FirstCall/ -- Action Products
International Inc. (Nasdaq: APII), a leading specialty toy manufacturer
emphasizing educational and non-violent branded toys for children in preschool
through primary grades, announced today that the Space Voyagers(R) astronaut
figure line has been selected by industry expert Dr. Toy (aka Stevanne
Auerbach, PhD) as one of the top 100 Best Children's Products and 10 Best
Socially Responsible Products for 2003.
Designated by Dr. Toy as products that "provide children with exciting new
learning tools that will help them not only to do better in school, but will
also provide more constructive activities after school," the highly-detailed
Space Voyagers figures, including Apollo Lunar Explorer Wolf Perry, Shuttle
Mission Specialist Steel Jones, and International Space Station Scientist Mack
Powers, were designed specifically for the specialty toy market, providing
retailers with the opportunity to carry non-violent action figures with an
educational twist that fits their store philosophy.
"[These figures] will help your child develop their imagination as they go
on their own adventures in space," said Dr. Toy. "Children love the mysteries
of space exploration and science and this is a great [line] for encouraging
their learning."
As part of the award selection, the astronaut figures will be featured
year-round on Dr. Toy's website (www.drtoy.com), accessed by "thousands of
visitors daily from around the world," while gold award seals will be applied
to packaging to notify consumers about Dr. Toy's endorsement. Joining
previous Dr. Toy award winners including the Buzz Aldrin Ultimate Saturn V
Rocket, I DIG Excavation Adventures(TM), and Kidz Workshop EZ Build
Projects(TM), the figures are currently available through specialty toy
stores, museums, theme parks, attractions, and online retailers.
ABOUT ACTION PRODUCTS INTERNATIONAL
Action Products International, Inc. is a manufacturer of educational and
non-violent toys for children in preschool through primary grades, emphasizing
fun, quality brands including Jay Jay The Jet Plane Wooden Adventure
System(TM), I Dig Dinosaurs(R) and I Dig Treasures(R) excavation activity
kits, Space Voyagers(R) ("The most authentic Space Toys on Earth"),
Climb@Tron(TM) window-climbing animals and robots, Play and Store(TM) themed
playsets, Kidz Workshop(TM) wooden projects, and Drop Zone Extreme(TM)
parachute toys. Its products are marketed and sold to specialty retailers,
museums, toy stores, theme parks, attractions, zoos, catalog companies,
Internet retailers, and educational markets in the United States and
worldwide. The Company is headquartered in Orlando, Florida, and its common
stock is listed on the NASDAQ Small Cap Market under the symbol "APII".
For more information on Action Products toys, email marketing@apii.com
Any statements that are not historical facts contained in this release are
forward-looking statements. It is possible that the assumptions made by
management for purposes of such statements may not materialize. Actual results
may differ materially from those projected or implied in any forward-looking
statements. Such statements may involve risks and uncertainties, including but
not limited to those relating to product demand, pricing, market acceptance,
the effect of economic conditions, and intellectual property rights and the
outcome of competitive products, risks in product development, the results of
financing efforts, the ability to complete transactions, and other factors
discussed from time to time in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to update or revise
any forward-looking statement for events or circumstances after the date on
which such statement is made.
SOURCE Action Products International, Inc.
/CONTACT: Warren Kaplan, Chairperson, +1-407-481-8007, ext. 723,
investor@apii.com, or Media - Greg Zesinger, +1-407-481-8007, ext.
722,gzesinger@apii.com, both of Action Products International, Inc./
/Web site: http://www.apii.com
http:// www.drtoy.com /
Oct-01-2003 12:02 GMT
Symbols:
US;APII
Source PRN PR Newswire
Categories:
NWI/REA NWR/FL NWS/AWD NWS/CHI MST/B/LIF MST/I/RCS MST/I/RTB
MST/I/SGD MST/I/TMF MST/R/US/FL TGT/PRN
Futures are up.. lets hope it continues..
TTXI SWINGING FOR THE FENCE...
This is a follow up to my previous PM's and Emails to you regarding the collection of TTXI data. You had promissed to return this information to all who sent it to you. To date I have not received this information. Please advise when you plan to forward.
KIWI chart
will consider going in when it surpasses resistance at .20
ERHC CHART
JRVR - Possible reversal???
WTAI - Possible reversal - one to radar..
MAGR breaks .115 break out IMHO
SIII - seems like new highs everyday....
SINX reversal of fortune????
PTSC a gapper to keep an eye on.
IMTO possible breakout over .04
FGWC if we can close above .05 looks like a possible breakout..
AVR news
vitar Announces $2,000,000 Private Placement
/FROM PR NEWSWIRE BOSTON 617-482-5355/
TO BUSINESS AND MEDICAL EDITORS:
Avitar Announces $2,000,000 Private Placement
CANTON, Mass., Sept. 30 /PRNewswire-FirstCall/ -- Avitar, Inc. (Amex: AVR)
announced today that it entered into a $2,000,000 private placement, which
raised gross proceeds of $1,000,000 in the first closing of convertible
preferred stock and warrants. An additional gross proceeds of $1,000,000 will
be raised in the second closing, which is expected to occur promptly after
shareholder approval, when additional convertible preferred stock and warrants
will be issued. All of the above securities have been placed with one
investor.
The securities sold in the first closing of the private placement were
1000 shares of 6% Convertible Preferred Stock, with Warrants to purchase
Common Stock. The $1,000,000 of Preferred Stock is convertible into Common
Stock at $0.15 per share, subject to adjustments, and the Warrants are
exercisable at $0.05 per share.
In the second closing, it is expected that an additional 1000 shares of 6%
Convertible Preferred Stock and Warrants to purchase Common Stock will be
issued. The second $1,000,000 of Preferred Stock will be convertible into
Common Stock at the greater of $0.15 per share or 80% of the 30-day moving
average of closing price of Avitar common stock on the day prior to the second
closing, and the Warrants issued in the second closing will be exercisable at
the greater of $0.075 per share or 50% of the aforementioned 30-day moving
average of closing price of Avitar common stock.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities mentioned in this
release. This release is being issued pursuant to and in accordance with Rule
135c under the Securities Act of 1933, as amended (the "Act"). The securities
described in this release have not been registered under the Act or any state
securities laws, and may not be offered or sold in the United States absent an
effective registration statement covering such securities or an applicable
exemption from such registration requirement.
Avitar, Inc. develops, manufactures and markets innovative and proprietary
products in the oral fluid diagnostic market, disease and clinical testing
market, and customized polyurethane applications used in the wound dressing
industry. Oral fluid diagnostics includes the estimated $1.5 billion drugs-of-
abuse testing market, which encompasses the corporate workplace and criminal
justice markets. Avitar's products include ORALscreen(TM), the world's first
non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, and
HAIRscreen(TM), a laboratory-based hair test for detecting long-term drug
abuse. Additionally, Avitar manufactures and markets HYDRASORB(TM), an
absorbent topical dressing for moderate to heavy exudating wounds. In the
estimated $25 billion in vitro diagnostics market, Avitar is developing
diagnostic strategies for disease and clinical testing. Some examples include
influenza, diabetes and pregnancy. For more information, see Avitar's website
at www.avitarinc.com.
Safe Harbor Statement. This release contains forward looking statements
that are subject to risks and uncertainties including financing risks and the
development and marketing of new applications and other risks that are
detailed from time to time in the Company's filings with the Securities and
Exchange Commission. In view of such risks and uncertainties, the Company's
actual results could differ materially from those anticipated in such forward
looking statements.
COMPANY CONTACT:
Avitar, Inc.
Jay Leatherman
781-821-2440
jleatherman@avitarinc.com
www.avitarinc.com
SOURCE Avitar, Inc.
/CONTACT: Jay Leatherman of Avitar, Inc., +1-781-821-2440,
jleatherman@avitarinc.com /
/Web site: http://www.avitarinc.com/
GENE NEWS
Genome Therapeutics Announces $9.55 Million Private Placement Financing
Business Editors/Health/Medical Writers
WALTHAM, Mass.--(BUSINESS WIRE)--Sept. 30, 2003--Genome
Therapeutics (Nasdaq: GENE) today announced that it has raised $9.55
million in gross proceeds (approximately $9 million in net proceeds
after expenses) through a private placement of common stock.
Approximately 3.8 million new shares of Genome Therapeutics common
stock have been issued to several new institutional shareholders, led
by Domain Public Equity Partners, L.P.
"The support and confidence of the respected institutional
investors participating in this financing provides us with the ability
to accelerate and expand our ongoing clinical studies for our lead
product candidate, Ramoplanin," said Steven M. Rauscher, Chairman and
Chief Executive Officer.
As part of the transaction, investors also received warrants to
purchase 1.9 million shares at an exercise price of $3.48 per share.
The warrants remain exercisable for a period of five years. Certain
existing investors have the right to purchase an additional 1.4
million shares on the same terms as the shares sold in this private
placement. Life Science Group, an investment banking firm focused
exclusively on the healthcare field, acted as placement agent.
The securities issued in the private placement have not been
registered under the Securities Act of 1933, as amended, and may not
be offered or sold in the United States absent registration under the
Securities Act and applicable state securities laws or an applicable
exemption from those registration requirements. Genome Therapeutics
has agreed to file a registration statement with the Securities and
Exchange Commission to register the resale of the shares of common
stock issued in the private placement, as well as the shares of common
stock issuable upon the exercise of the warrants issued in the private
placement.
This notice shall not constitute an offer to sell, or the
solicitation of an offer to buy, any securities of Genome
Therapeutics.
About Ramoplanin
Genome Therapeutics' lead product candidate, Ramoplanin, is an
investigational new drug in clinical development for the prevention,
treatment and control of serious hospital-based infections. The
Company licensed the North American rights to Ramoplanin from Vicuron
Pharmaceuticals. Ramoplanin has Fast Track status from the FDA and is
currently in a Phase III clinical trial for the prevention of VRE
bloodstream infections and in a Phase II study for treating
Clostridium difficile-associated diarrhea (CDAD). Existing preclinical
data suggest Ramoplanin may have potential in controlling several
antibiotic-resistant, Gram-positive bacteria such as
vancomycin-resistant enterococci (VRE), methicillin-resistant
Staphylococcus aureus and vancomycin-resistant Staphylococcus aureus.
The antibiotic has also been shown to be bactericidal in vitro against
Clostridium difficile. In a Phase II study, Ramoplanin was shown to be
highly effective at decolonizing patients carrying VRE in their
gastrointestinal (GI) tracts. A pilot study is also underway examining
Ramoplanin's potential role in controlling the spread of nosocomial
bacteria.
About Genome Therapeutics
Genome Therapeutics is a biopharmaceutical company focused on the
discovery and development of pharmaceutical products for specialty
markets. The Company's lead product candidate, Ramoplanin, is in
development for the prevention, treatment and control of serious
hospital-based infections. Ramoplanin is currently in a Phase III
clinical trial for the prevention of bloodstream infections caused by
vancomycin-resistant enterococci (VRE), and in a Phase II clinical
trial for the treatment of Clostridium difficile-associated diarrhea
(CDAD). Genome Therapeutics' biopharmaceutical portfolio also includes
seven major product discovery and development alliances with
pharmaceutical companies including Amgen, AstraZeneca, bioMerieux,
Schering-Plough and Wyeth.
This news release may contain forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements represent
our management's judgment regarding future events. Forward-looking
statements typically are identified by use of terms such as "may,"
"will," "should," "plan," "expect," "intend," "anticipate,"
"estimate," and similar words, although some forward-looking
statements are expressed differently. We do not plan to update these
forward-looking statements. You should be aware that our actual
results could differ materially from those contained in the
forward-looking statements due to a number of risks affecting our
business. These risk factors include risks related to our lead product
candidate, Ramoplanin, such as (i) our inability to obtain regulatory
approval to commercialize Ramoplanin due to negative, inconclusive or
insufficient clinical data and (ii) delays in the progress of our
clinical trials for Ramoplanin, and increased cost, due to the pace of
enrollment of patients in the trials or fluctuations in the infection
rate of enrolled patients. We are also subject to risks related to our
inability or the inability of our alliance partners to (i)
successfully develop products based on our genomics information, (ii)
obtain the necessary regulatory approval for such products, (iii)
effectively commercialize any products developed before our
competitors are able to commercialize competing products or (iv)
obtain and enforce intellectual property rights. In addition, we are
subject to the risk factors set forth in Exhibit 99.1 to the Company's
Annual Report on Form 10-K for the year ended December 31, 2002 and
those set forth in other filings that we may make with the Securities
and Exchange Commission from time to time.
--30--MA/bo*
CONTACT: Genome Therapeutics
Investor Relations
Christopher Taylor, 781-398-2466
or
Media Relations
Sarah Emond, 781-398-2544
KEYWORD: MASSACHUSETTS
INDUSTRY KEYWORD: BANKING PHARMACEUTICAL MEDICAL BIOTECHNOLOGY
SOURCE: Genome Therapeutics
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Sep-30-2003 20:30 GMT
Symbols:
US;GENE
Source BW Business Wire
Categories:
MST/I/BNK MST/I/BTC MST/I/DRG MST/I/MTC MST/R/US/MA TGT/BWN
CMGI Reports Fourth Quarter and Full Fiscal Year 2003 Financial Results
Business Editors/High-Tech Writers
CHARLESTOWN, Mass.--(BUSINESS WIRE)--Sept. 30, 2003--
With Major Restructuring Substantially Complete, CMGI Exits
Fiscal Year With Cash, Cash Equivalents and Marketable Securities
in Excess of $275 Million
CMGI, Inc. (Nasdaq: CMGI) today reported financial results for its
fourth quarter and full fiscal year ended July 31, 2003.
Fourth Quarter
CMGI reported net revenue from continuing operations of $97.9
million for the fourth fiscal quarter ended July 31, 2003. This
compares to net revenue of $106.1 million for the quarter ended April
30, 2003, a decrease of $8.2 million from continuing operations. This
decrease was primarily due to lower order volumes from a major
original equipment manufacturer (OEM) customer, as well as the
migration of certain other work to Asia. The addition of new projects
in supply chain management and literature fulfillment was not
sufficient to mitigate the softness in the supply chain management
revenue.
CMGI reported an operating loss from continuing operations of
$34.0 million for the fourth quarter ended July 31, 2003, compared to
an operating loss of $27.5 million for the third quarter ended April
30, 2003. The fourth quarter operating loss from continuing operations
included charges related to the amortization of stock-based
compensation and depreciation totaling $2.9 million and net
restructuring charges of $26.2 million. The Company's restructuring
charges in the fourth quarter included a $15.4 million charge related
to the buyout of the Company's lease for its former headquarters
building in Andover Massachusetts, and a $4.6 million charge related
to facility lease obligations from SalesLink's restructuring of its
North America supply chain capacity. Included in the third quarter
operating loss from continuing operations were charges related to the
amortization of stock-based compensation and depreciation totaling
$2.9 million, and long-lived asset impairment and net restructuring
charges of $20.4 million. The Company's $19.9 million of net
restructuring charges in the third quarter of fiscal 2003 primarily
included $14.9 million of restructuring charges related to facility
and equipment lease obligations and asset write-offs at certain U.S.
based operations of SalesLink.
"The elimination of the Andover lease was a major milestone in
reducing our lease obligations. This transaction reduced future lease
and lease related operating expenses by approximately $50.0 million,
for an annual cash savings of approximately $7.0 million," said Tom
Oberdorf, Chief Financial Officer.
CMGI reported a net loss of $16.4 million or loss per share of
($0.04) for the fourth quarter of fiscal 2003, compared to net income
of $76.9 million or $0.20 earnings per share for the third quarter
ended April 30, 2003. Net loss in the fourth quarter of fiscal 2003
included income from discontinued operations of $13.2 million or $0.03
earnings per share. The income from discontinued operations during the
fourth quarter of fiscal 2003 included a $10.5 million benefit related
to the reversal of net liabilities of a subsidiary that entered into
an assignment for the benefit of creditors in June 2001. The reversal
was triggered by the conclusion of the assignment for the benefit of
creditors proceedings as they related to CMGI. Net income in the third
quarter of fiscal 2003 included income from discontinued operations of
$117.8 million or $0.30 earnings per share. The income from
discontinued operations during the third quarter of fiscal 2003
included a gain by AltaVista of approximately $97.6 million on the
sale of its assets and business operations, a gain of approximately
$1.6 million on the sale of Yesmail, the write-off of approximately
$35.6 million of minority interest in ProvisionSoft, which ceased
operations during the third quarter, and approximately $2.8 million of
loss adjustments related to the Company's January 31, 2003 "held for
sale" loss estimates for Tallan and uBid. The fourth quarter loss from
continuing operations of $29.6 million improved by $11.3 million from
the third quarter amount of $40.9 million.
Excluding the effects of charges related to depreciation,
amortization, long-lived asset impairment and restructuring, CMGI
reported a non-GAAP operating loss(1) from continuing operations of
$4.9 million for the fourth quarter ended July 31, 2003 versus a
non-GAAP operating loss(1) from continuing operations of $4.3 million
in the third quarter ended April 30, 2003. The increase in non-GAAP
operating loss(1) from continuing operations in the fourth quarter was
primarily the result of lower sales levels in the fourth quarter as
compared to the third quarter.
The Company believes that its non-GAAP measure of operating
income/(loss) from continuing operations ("non-GAAP operating
income/(loss)(1)") provides investors with a useful supplemental
measure of the Company's operating performance by excluding the impact
of one-time gains/(losses), non-cash charges, and restructuring
activities. Historically, the Company has recorded significant
one-time gains/(losses), and impairment and restructuring charges and
therefore management uses non-GAAP operating income/(loss)(1) to
assist in evaluating the Company's operating performance. These
non-GAAP results should be evaluated in light of the Company's
financial results prepared in accordance with United States generally
accepted accounting principles ("GAAP"). A table reconciling the
Company's non-GAAP operating loss to its GAAP operating income/(loss)
is included in the consolidated financial statements in this release.
As of July 31, 2003, CMGI had consolidated cash, cash equivalents
and marketable securities of $276.1 million, versus consolidated cash,
cash equivalents and marketable securities of $250.9 million for the
prior quarter. Cash, cash equivalents and marketable securities
increased primarily due to a $45.5 million increase in value during
the fourth quarter of shares of Overture Services, Inc. ("Overture")
common stock held by AltaVista. Subsequent to the fiscal year end, all
shares of Overture common stock were sold.
George McMillan, President and Chief Executive Officer of CMGI,
Inc., said: "One factor contributing to the revenue softness in the
supply chain business is the migration of programs to Asia, more
specifically, China, where CMGI is actively pursuing expansion. The
liquidity position of CMGI is exceptionally strong, and provides both
a considerable source for reinvestment in our global supply chain and
literature fulfillment business, and a long-term liquidity cushion."
Fiscal Year
CMGI reported net revenue from continuing operations of $437.0
million for the fiscal year ended July 31, 2003. This compares to net
revenue from continuing operations of $168.5 million for the fiscal
year ended July 31, 2002, an increase of $268.5 million. This increase
was the result of the revenue contributions from SalesLink's SL Supply
Chain subsidiary, which was acquired in July 2002, partially offset by
a decline in SalesLink's supply chain management business.
CMGI reported an operating loss from continuing operations of
$92.4 million for the fiscal year ended July 31, 2003, compared to an
operating loss from continuing operations of $75.7 million for the
fiscal year ended July 31, 2002. Included in the fiscal 2003 operating
loss from continuing operations were charges related to the
amortization of stock-based compensation and depreciation totaling
$10.8 million, and long-lived asset impairment and net restructuring
charges of $55.8 million. Included in the fiscal 2002 operating loss
from continuing operations were charges related to the amortization of
intangible assets and stock-based compensation and depreciation
totaling $19.2 million, and long-lived asset impairment and net
restructuring charges of ($0.6) million. The Company's $55.3 million
of restructuring charges in fiscal 2003 primarily included a $15.4
million charge related to the early termination of the Company's lease
for its former headquarters facility in Andover, Massachusetts, $19.5
million of restructuring charges related to facility and equipment
lease obligations and asset write-offs at certain U.S. based
operations of the Company's SalesLink subsidiary, and $6.6 million of
charges related to certain corporate equipment lease obligations.
CMGI reported a net loss of $216.3 million for fiscal 2003,
compared to a net loss of $524.9 million for fiscal 2002. CMGI's net
loss available to common stockholders for fiscal 2003 was $216.3
million, or ($0.55) loss per share, compared to a net loss available
to common stockholders of $463.7 million, or ($1.22) loss per share,
for fiscal 2002. The net loss in fiscal 2003 included a loss from
discontinued operations of $81.6 million, or ($0.21) loss per share.
The loss from discontinued operations during fiscal 2003 primarily
included operating losses from discontinued operations of $206.2
million, partially offset by a gain by AltaVista of approximately
$99.4 million on the sale of its assets and business operations, and
the write-off of approximately $35.6 million of minority interest in
ProvisionSoft. The net loss in fiscal 2002 included a loss from
discontinued operations of $540.7 million, or ($1.43) loss per share.
Excluding the effects of charges related to depreciation,
amortization, long-lived asset impairment and restructuring, CMGI
reported a non-GAAP operating loss(1) from continuing operations of
$25.8 million for the fiscal year ended July 31, 2003 versus a
non-GAAP operating loss(1) from continuing operations of $57.1 million
in the fiscal year ended July 31, 2002. The decrease in non-GAAP
operating loss(1) from continuing operations in fiscal 2003, as
compared to fiscal 2002, is primarily due to the Company's
restructuring efforts in fiscal 2003.
Basis of Presentation
The Company's results of continuing operations discussed herein
exclude the results of operations of the Company's former operating
companies AltaVista and uBid, each of which sold substantially all of
their assets, Engage, NaviSite, Yesmail, and Tallan, each of which
were divested, and ProvisionSoft, which ceased operations, during the
fiscal year ended July 31, 2003. The results of operations of each of
these former operating companies have been reported as discontinued
operations in accordance with generally accepted accounting
principles.
As of July 31, 2003, the Company's operating businesses included
its wholly-owned subsidiary, SalesLink Corporation ("SalesLink") and
SL Supply Chain Services International Corp., a wholly-owned
subsidiary of SalesLink, each of which operate within the Company's
eBusiness and Fulfillment segment. The Company also continues to hold
investments in various companies through its @Ventures venture capital
affiliates.
Conference Call Scheduled for September 30th
CMGI will hold a conference call to discuss its fourth quarter and
full fiscal year 2003 results at 5:00 p.m. EDT on September 30, 2003.
Investors can listen to the conference call on the Internet at
www.cmgi.com/investor. To listen to the live call, go to the Web site
at least 15 minutes prior to the start time to download and install
the necessary audio software.
About CMGI
CMGI, Inc. (Nasdaq: CMGI) provides technology and commerce
solutions that help businesses market, sell and distribute their
products and services. CMGI offers industry-leading global supply
chain management and distribution and fulfillment services. For
additional information, see www.cmgi.com.
(1) The non-GAAP operating results are not a recognized measure
for financial statement presentation under the United States generally
accepted accounting principles (U.S. GAAP). Non-U.S. GAAP earnings
measures do not have any standardized definition and are therefore
unlikely to be comparable to similar measures presented by other
reporting companies. This non-GAAP measure is provided to assist
readers in evaluating CMGI's operating performance and each of the
items listed (depreciation, amortization of assets and stock-based
compensation, long-lived asset impairment and restructuring) were
excluded because they were considered to be of a non-operational
nature. Readers are encouraged to consider this non-GAAP measure in
conjunction with CMGI's U.S. GAAP results. Previously, CMGI referred
to this measure as "pro forma operating income/(loss)."
This release contains forward-looking statements, which address a
variety of subjects including, for example, the expected future
benefits of CMGI's restructuring activities, CMGI's planned
international expansion efforts, and the expected ability of CMGI to
preserve and utilize its capital resources to grow its businesses. All
statements other than statements of historical fact, including without
limitation, those with respect to CMGI's goals, plans and strategies
set forth herein are forward-looking statements. The following
important factors and uncertainties, among others, could cause actual
results to differ materially from those described in these
forward-looking statements: CMGI's success, including its ability to
decrease its cash burn rate, improve its cash position, expand its
operations and revenues and reach profitability, depends on its
ability to execute on its business strategy and the continued and
increased demand for and market acceptance of its products and
services; CMGI may not be able to expand its operations in accordance
with its business strategy, CMGI may experience difficulties
integrating technologies, operations and personnel in accordance with
its business strategy; CMGI derives a significant portion of its
revenue from a small number of customers and the loss of any of those
customers would significantly damage CMGI's financial condition and
results of operations; and increased competition and technological
changes in the markets in which CMGI competes. For a detailed
discussion of cautionary statements that may affect CMGI's future
results of operations and financial results, please refer to CMGI's
filings with the Securities and Exchange Commission, including CMGI's
most recent Quarterly Report on Form 10-Q. Forward-looking statements
represent management's current expectations and are inherently
uncertain. We do not undertake any obligation to update
forward-looking statements made by us.
-0-
*T
CMGI, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
(Unaudited)
Three months ended Fiscal Year ended
July 31, April 30, July 31, July 31, July 31,
2003 2003 2002 2003 2002
-------- -------- --------- --------- ---------
Net revenue $ 97,882 $106,109 $ 48,724 $ 436,987 $ 168,476
Operating expenses:
Cost of revenue 90,389 98,582 41,164 403,883 152,140
Research and
development - - 463 332 4,732
Selling 1,446 1,066 19,748 6,792 28,357
General and
administrative 13,741 13,557 3,885 62,336 54,598
Amortization of
intangible assets
and stock-based
compensation 54 55 (311) 218 4,941
Impairment of long-
lived assets - 432 154 456 2,482
Restructuring, net 26,204 19,938 3,652 55,348 (3,118)
-------- -------- --------- --------- ---------
Total operating
expenses 131,834 133,630 68,755 529,365 244,132
-------- -------- --------- --------- ---------
Operating loss (33,952) (27,521) (20,031) (92,378) (75,656)
Other income
(deductions):
Other gains
(losses), net 4,363 (11,608) (34,071) (41,317) (67,983)
Minority interest 69 99 - 319 -
Equity in losses of
affiliates 163 (1,049) (12) (1,774) (15,408)
Interest income 734 710 4,286 3,396 14,387
Interest (expense)
recovery, net (409) (432) 16,605 321 22,029
-------- -------- --------- --------- ---------
Total 4,920 (12,280) (13,192) (39,055) (46,975)
-------- -------- --------- --------- ---------
Loss from continuing
operations before
income taxes and
extraordinary item (29,032) (39,801) (33,223) (131,433) (122,631)
Income tax expense
(benefit) 582 1,073 (2,881) 3,249 (7,096)
-------- -------- --------- --------- ---------
Loss from continuing
operations before
extraordinary item (29,614) (40,874) (30,342) (134,682) (115,535)
Discontinued
operations, net of
income taxes:
Income (loss) from
discontinued
operations 13,224 117,806 (159,763) (81,626) (540,664)
Extraordinary gain on
retirement of debt,
net of income tax - - - - 131,281
-------- -------- --------- --------- ---------
Net income (loss) (16,390) 76,932 (190,105) (216,308) (524,918)
Preferred stock
accretion - - - - (2,301)
Gain on repurchase of
Series C Convertible
Preferred Stock - - - - 63,505
-------- -------- --------- --------- ---------
Net income (loss)
available to common
stockholders $(16,390)$ 76,932 $(190,105)$(216,308)$(463,714)
======== ======== ========= ========= =========
Basic and diluted
earnings (loss) per
share available to
common stockholders:
Loss from
continuing
operations before
extraordinary
item $ (0.07)$ (0.10)$ (0.08)$ (0.34)$ (0.14)
Earnings (loss)
from discontinued
operations $ 0.03 $ 0.30 $ (0.40)$ (0.21)$ (1.43)
Extraordinary gain
on retirement of
debt, net of
income tax $ - $ - $ - $ - $ 0.35
-------- -------- --------- --------- ---------
Earnings (loss)
available to
common
stockholders $ (0.04)$ 0.20 $ (0.48)$ (0.55)$ (1.22)
======== ======== ========= ========= =========
Shares used in
computing basic and
diluted earnings
(loss) per share 394,514 393,542 392,380 393,455 379,800
======== ======== ========= ========= =========
CMGI, Inc. and Subsidiaries
Consolidated Statements of Operations Information
(In thousands)
(Unaudited)
Three months ended Fiscal Year ended
July 31, April 30, July 31, July 31, July 31,
2003 2003 2002 2003 2002
-------- -------- -------- -------- --------
Net revenue:
-------------------------
eBusiness and
Fulfillment $ 97,545 $105,974 $ 48,401 $435,879 $154,493
Enterprise Software and
Services - - 118 227 1,289
Managed Application
Services 337 135 205 881 6,158
Portals - - - - 6,536
-------- -------- -------- -------- --------
$ 97,882 $106,109 $ 48,724 $436,987 $168,476
======== ======== ======== ======== ========
Operating income (loss):
-------------------------
eBusiness and
eBusiness and
Fulfillment $ (7,036)$(15,028)$ 525 $(20,021)$ (1,090)
Enterprise Software and
Services 120 - (3,354) (846) (13,957)
Managed Application
Services (904) (149) 27 (653) 2,368
Portals (436) (450) 4,644 (17) (1,747)
Other (25,696) (11,894) (21,873) (70,841) (61,230)
-------- -------- -------- -------- --------
$(33,952)$(27,521)$(20,031)$(92,378)$(75,656)
======== ======== ======== ======== ========
Non-GAAP operating income
(loss):
-------------------------
eBusiness and
Fulfillment $ 695 $ 1,767 $ 2,429 $ 7,352 $ 5,923
Enterprise Software and
Services 50 - (2,673) (861) (9,653)
Managed Application
Services 652 136 1,024 1,212 (12,056)
Portals 55 (7) 5,568 1,011 5,628
Other (6,333) (6,157) (20,138) (34,487) (46,916)
-------- -------- -------- -------- --------
$ (4,881)$ (4,261)$(13,790)$(25,773)$(57,074)
======== ======== ======== ======== ========
Note: Non-GAAP operating income (loss) represents total operating
income (loss), excluding net charges related to depreciation,
amortization of intangible assets and stock-based compensation,
long-lived asset impairment and restructuring.
TABLE RECONCILING GAAP OPERATING INCOME (LOSS) TO
NON-GAAP OPERATING INCOME (LOSS)
GAAP Operating Loss $(33,952)$(27,521)$(20,031)$(92,378)$(75,656)
Adjustments:
Depreciation 2,813 2,835 2,746 10,583 14,277
Amortization of
intangible assets
and stock-based
compensation 54 55 (311) 218 4,941
Long-lived asset
impairment - 432 154 456 2,482
Restructuring 26,204 19,938 3,652 55,348 (3,118)
-------- -------- -------- -------- --------
Non-GAAP Operating Loss $ (4,881)$ (4,261)$(13,790)$(25,773)$(57,074)
======== ======== ======== ======== ========
*T
--30--SK/bo*
CONTACT: CMGI, Inc.
Investors-Financial
Tom Oberdorf, 617-886-4523
ir@cmgi.com
KEYWORD: MASSACHUSETTS
INDUSTRY KEYWORD: SOFTWARE E-COMMERCE INTERNET
COMPUTERS/ELECTRONICS CONFERENCE CALLS EARNINGS
SOURCE: CMGI, Inc.
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Sep-30-2003 20:00 GMT
Symbols:
DE;CGO DE;CGOF DE;CGOS DE;CGOX US;CMGI
Source BW Business Wire
Categories:
MST/I/ISS MST/I/NET MST/I/SOF MST/R/US/MA MST/S/ERN MST/S/MET TGT/BWN
AMEP mms lining up on bid side...
TCET name change
TerenceNet, Inc. Announces Name Change to Atlantic Synergy, Inc.
/FROM PR NEWSWIRE MIAMI 305-461-8666/
TO BUSINESS AND TECHNOLOGY EDITORS:
TerenceNet, Inc. Announces Name Change to Atlantic Synergy, Inc.
FORT PIERCE, Fla., Sept. 30 /PRNewswire-FirstCall/ -- TerenceNet, Inc.
(OTC Bulletin Board: TCET) has been renamed Atlantic Synergy, Inc. The new
trading symbol, active immediately, will be the newly assigned ticker symbol
ASGY on the OTC Bulletin Board.
Terence Channon, CEO of Atlantic Synergy stated, "This new name more
accurately represents our continually diversifying revenue streams and
business models. Atlantic Synergy will better reflect our business development
initiatives. We are pleased with our progress in expanding beyond our core
technology services and solutions. Without diluting the focus of our legacy
business services, we have developed additional revenue streams that will
expand our scope nationally."
Chairman of the Board Stephen Day of Columbia, Maryland added, "This name
change to Atlantic Synergy reflects a new and better foundation for additional
business units and revenue channels. The realignment of our management
structure will enhance our ability to grow through mergers and acquisitions."
For additional information, contact Stephen Day, Chairman, Atlantic
Synergy, Inc., 6 Avenue A, Ft. Pierce, FL 34950 U.S.A. Phone 443-864-8721,
email info@atlanticsynergy.com. Information is also available online at
www.atlanticsynergy.com.
Special Information Regarding Forward-Looking Statements
Some of the statements in this communication are "forward-looking
statements." These forward-looking statements involve certain known and
unknown risks, uncertainties and other factors which may cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by these
forward-looking statements. These factors include, among others, the factors
set forth above under "Risk Factors." The words "believe," "expect,"
"anticipate," "intend," "plan," and similar expressions identify forward-
looking statements. We caution you not to place undue reliance on these
forward-looking statements. We undertake no obligation to update and revise
any forward-looking statements or to publicly announce the result of any
revisions to any of the forward-looking statements in this document to reflect
any future or developments.
SOURCE TerenceNet, Inc./Atlantic Synergy, Inc.
/CONTACT: Stephen Day, Chairman, Atlantic Synergy, Inc., +1-443-864-8721,
or info@atlanticsynergy.com /
/Web site: http://www.terencenet.com
http://www.atlanticsynergy.com /
Sep-30-2003 19:20 GMT
Symbols:
US;TCET
Source PRN PR Newswire
Categories:
NWI/CPR NWI/MLM NWI/OTC NWR/FL NWR/MD MST/I/CPM MST/I/MKT MST/I/NET
MST/R/US/FL MST/R/US/MD TGT/PRN
Just to keep in mind MAGR
Looks like money is starting to come back into the markets..
Lets keep hoping...
dow down .63.33
naz down 20.45
Roses are red....
Ohhh sorry thats my portfolio
Hey Omni we need you to get on the radio and feature some of the stocks I'm holding... ...
Hope everyone if following NNCO
Got a feeling there will be alot of PRs starting tomorrow and next week to get PPS back up...
IDNW NEWS
iDial Networks Conference Call Scheduled
Business Editors/High-Tech Writers
THE WOODLANDS, Texas--(BUSINESS WIRE)--Sept. 30, 2003--iDial
Networks, Inc. (OTCBB:IDNW) today announced that a conference call
will be held on Wednesday, October 1, 2003 at 11:00 a.m. central time
(12:00 p.m. eastern) to discuss the Company's recent acquisition of
GlobalNet, Inc.
What: iDial Networks, Inc. Conference Call
When: Wednesday, October 1, 2003 at 11:00 a.m. central time
How: Dial 877-691-0879 to access the call
Who: Mark T. Wood, Chairman and Chief Executive Officer;
Thomas J. Seifert, Chief Financial Officer
About GlobalNet, Inc.
GlobalNet, Inc. is one of the top ten U.S. service providers of
outbound traffic to Latin America and counts among its customers more
than 30 Tier 1 and Tier 2 carriers. GlobalNet provides international
voice, data, fax and Internet services on a wholesale basis over a
private IP network to international carriers and other communication
service providers in the United States and internationally.
GlobalNet's state-of--the-art IP network, utilizing the convergence of
voice and data networking, offers customers economical pricing, global
reach and an intelligent platform that guarantees fast delivery of
value-added services and applications.
About iDial Networks, Inc.:
iDial Networks, Inc., (http://www.idialnetworks.com), is an
application service provider in leading communication technologies,
provides a wide range of Voice over Internet Protocol (VoIP) services,
Internet-activated applications and products that bring affordable
telecommunications services to users around the globe. The company is
building a next generation VoIP and TDM network based on carrier class
technologies from Cisco Systems (Nasdaq:CSCO) and Microsoft
(Nasdaq:MSFT).
Safe Harbor for Forward-Looking Statements:
Except for historical information contained herein, the statements
in this news release are forward-looking statements that are made
pursuant to the Safe Harbor provisions of the Private Securities
Reform act of 1995. Forward-looking statements involve known and
unknown risks and uncertainties, which may cause the Company's actual
results in the future periods to differ materially from forecasted
results. These risks and uncertainties include, among other things,
product price, volatility, product demand, market competition, risk
inherent in the Company's domestic and international operations,
imprecision in estimating product reserves and the Company's ability
to replace and expand its holdings.
--30--EF/da*
CONTACT: iDial Networks, Inc., The Woodlands
Mark T. Wood, 281-652-1305
investors@idnw.com
KEYWORD: TEXAS INTERNATIONAL LATIN AMERICA
INDUSTRY KEYWORD: TELECOMMUNICATIONS NETWORKING E-COMMERCE
INTERNET ADVISORY CONFERENCE CALLS
SOURCE: iDial Networks, Inc.
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Sep-30-2003 18:07 GMT
Symbols:
US;IDNW
Source BW Business Wire
Categories:
MST/I/CMT MST/I/ISS MST/I/NET MST/I/TEL MST/R/LTM MST/R/US/TX
MST/S/MET TGT/BWN
Hey chipster... Im mad, the stock you told me about just went up .10 a share (CYGX) and I was unable to buy more...